Top

Published in:

01-08-2013 | Review Article

Treatment of Opioid-Induced Constipation: Focus on the Peripheral μ-Opioid Receptor Antagonist Methylnaltrexone

Author: Richard L. Rauck

Published in: Drugs | Issue 12/2013

Abstract

Most prescribed opioids exert their analgesic effects via activation of central μ-opioid receptors. However, μ-opioid receptors are also located in the gastrointestinal (GI) tract, and activation of these receptors by opioids can lead to GI-related adverse effects, in particular opioid-induced constipation (OIC). OIC has been associated with increased use of healthcare resources, increased healthcare costs, and decreased quality of life for patients. Nonpharmacologic (e.g., increased fiber uptake) and pharmacologic agents (e.g., laxatives) may be considered for the treatment and prevention of OIC. However, many interventions, such as laxatives alone, are generally insufficient to reverse OIC because they do not target the underlying cause of OIC, opioid activation of μ-opioid receptors in the GI tract. Therefore, there has been keen interest in antagonism of the μ-opioid receptor in the periphery to inhibit the effects of opioids in the GI tract. In this review, currently available pharmacologic therapies for the treatment and prevention of OIC are summarized briefly, with a primary focus on the administration of the peripheral μ-opioid receptor antagonist methylnaltrexone bromide in patients with OIC and advanced illness who are receiving palliative care. Also, clinical trial data of methylnaltrexone treatment in patients with OIC and other pain conditions (i.e., chronic noncancer pain and pain after orthopedic surgery) are reviewed. Data support that methylnaltrexone is efficacious for the treatment of OIC and has a favorable tolerability profile.

American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S1–4.CrossRef

McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3 Suppl):3–9.PubMed

Hsieh C. Treatment of constipation in older adults. Am Fam Physician. 2005;72(11):2277–84.PubMed

Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91.PubMedCrossRef

Schumacher MA, Basbaum AI, Way WL. Opioid analgesics and antagonists. In: Katzung BG, editor. Basic and Clinical Pharmacology. New York: McGraw-Hill Medical; 2009. p. 531–52.

Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1–3):11–7.PubMedCrossRef

Yuan CS, Foss JF, O’Connor M, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996;59(4):469–75.PubMedCrossRef

Manara L, Bianchi G, Ferretti P, et al. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther. 1986;237(3):945–9.PubMed

Tavani A, Bianchi G, Ferretti P, et al. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci. 1980;27(23):2211–7.PubMedCrossRef

10.

Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther. 2010;27(10):714–30.PubMedCrossRef

11.

Chou R, Fanciullo GJ, Fine PG, American Pain Society; American Academy of Pain Medicine Opioid Guidelines Panel, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.PubMedCrossRef

12.

Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847–65.PubMedCrossRef

13.

Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224–32.PubMedCrossRef

14.

Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998;12(5):375–82.PubMedCrossRef

15.

Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23(3):231–41.PubMedCrossRef

16.

Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manage Care. 2010;19(3):44–51.

17.

Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manage. 2009;5(3):137–44.

18.

Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10(1):35–42.PubMedCrossRef

19.

Penning-van Beest FJ, van den Haak P, Klok RM, et al. Quality of life in relation to constipation among opioid users. J Med Econ. 2010;13(1):129–35.PubMedCrossRef

20.

Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835–42.PubMedCrossRef

21.

Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181–7.PubMedCrossRef

22.

Ternent CA, Bastawrous AL, Morin NA, et al. Practice parameters for the evaluation and management of constipation. Dis Colon Rectum. 2007;50(12):2013–22.PubMedCrossRef

23.

Walters JB, Montagnini M. Current concepts in the management of opioid-induced constipation. J Opioid Manage. 2010;6(6):435–44.CrossRef

24.

Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S5–21.PubMedCrossRef

25.

Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—guidance. Pain Physician. 2012;15(Suppl 3):S67–116.PubMed

26.

Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68.PubMedCrossRef

27.

Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;(1):CD003448.

28.

Thomas JR, Cooney GA, Slatkin NE. Palliative care and pain: new strategies for managing opioid bowel dysfunction. J Palliat Med. 2008;11(Suppl 1):S1–19.PubMedCrossRef

29.

Tack J. Current and future therapies for chronic constipation. Best Pract Res Clin Gastroenterol. 2011;25(1):151–8.PubMedCrossRef

30.

Bader S, Jaroslawski K, Blum HE, et al. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201–11.PubMed

31.

Emmanuel A. Current management strategies and therapeutic targets in chronic constipation. Ther Adv Gastroenterol. 2011;4(1):37–48.CrossRef

32.

Amitiza (lubiprostone) capsules [package insert]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2013.

33.

Entereg (alvimopan) capsules [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc., 2012.

34.

Relistor (methylnaltrexone bromide) subcutaneous injection [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc.; 2012.

35.

van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, et al. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med. 2007;35(12):2726–31.PubMedCrossRef

36.

Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;(3):CD004847.

37.

Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25(5):494–503.PubMedCrossRef

38.

Fallon M, O’Neill B. ABC of palliative care. Constipation and diarrhoea. BMJ. 1997;315(7118):1293–6.PubMedCrossRef

39.

Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10(2):135–44.PubMedCrossRef

40.

Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23(1):48–53.PubMedCrossRef

41.

Cassel JA, Daubert JD, DeHaven RN. [³H]alvimopan binding to the μ opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005;520:29–36.PubMedCrossRef

42.

Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047–56.PubMedCrossRef

43.

A study of S-297995 for the treatment of opioid-induced constipation in subjects with non-malignant chronic pain receiving opioid therapy [ClinicalTrials.gov identifier NCT01443403]. 2012 Nov 27 [online]. Bethesda: US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01443403. (Accessed 1 Feb 2013).

44.

Paulson D, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized clinical trial. J Pain. 2005;6(3):184–92.PubMedCrossRef

45.

Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428–40.PubMedCrossRef

46.

Jansen J-P, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):185–93.PubMedCrossRef

47.

Irving G, Pénzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):175–84.PubMedCrossRef

48.

Bream-Rouwenhorst HR, Cantrell MA. Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009;66(14):1267–77.PubMedCrossRef

49.

Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–78.PubMedCrossRef

50.

Carman WJ, Su S, Coo SF, et al. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011;20:754–62.PubMedCrossRef

51.

Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46.PubMed

52.

Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–43.PubMedCrossRef

53.

Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38(5):683–90.PubMedCrossRef

54.

Slatkin NE, Lynn R, Su C, et al. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011;42(5):754–60.PubMedCrossRef

55.

Corken Mackey A, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage. 2010;40(1):e1–3.CrossRef

56.

Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–62.PubMedCrossRef

57.

Michna E, Weil AJ, Duerden M, et al. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. Pain Med. 2011;12(8):1223–30.PubMedCrossRef

58.

Blonsky E, Watier A, Schulman S, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain: open-label results [abstract no. 149]. Reg Anesth Pain Med. 2009;34(5):98.

59.

Webster L, Michna E, Khan A, et al. The long-term efficacy of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain [abstract no. 376]. J Pain. 2011;12(Suppl 4):P70.

60.

Webster L, Michna E, Khan A, et al. The long-term safety of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain [abstract no. 378]. J Pain. 2011;12(Suppl 4):P70.

61.

Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7(2):67–72.PubMedCrossRef

62.

Cryer BL, Katz S, Vallejo R, et al. A phase 3, randomized, double-blind, placebo- controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain [abstract no. 906]. Gastroenterology. 2010;138(5 Suppl 1):S129.

63.

Jamal MM, Mareya SM, Woldegeorgis F, et al. Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial [poster no. 848a]. Digestive Diseases Week 2012, San Diego; May 19–22, 2012.

64.

Spierings E, Joswick T, Lindner E, et al. Long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction in patients with chronic, non-cancer pain: results of a phase 3, open-label clinical trial [abstract no. 322]. Am J Gastroenterol. 2012;107(Suppl 1):S138.

65.

Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997;273(5 Pt 2):H2534–8.PubMed

66.

Pasricha PJ. Desperately seeking serotonin… A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology. 2007;132(7):2287–90.PubMedCrossRef

67.

Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745–67.PubMedCrossRef

68.

Zelnorm (tegaserod maleate) information. 2012 May 11 [online]. Silver Spring, MD: US Department of Health and Human Services, US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm (Accessed 1 Feb 2013).

69.

Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912–21.PubMedCrossRef

70.

Quigley EMM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. 2012;5(1):23–30.PubMedCrossRef

Title: Treatment of Opioid-Induced Constipation: Focus on the Peripheral μ-Opioid Receptor Antagonist Methylnaltrexone
Author: Richard L. Rauck
Publication date: 01-08-2013
Publisher: Springer International Publishing
Published in: Drugs / Issue 12/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0084-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment of Opioid-Induced Constipation: Focus on the Peripheral μ-Opioid Receptor Antagonist Methylnaltrexone

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2013

Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies

Recombinant Trivalent Influenza Vaccine (Flublok®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults

Extra-Esophageal Manifestations of Gastroesophageal Reflux Disease: Diagnosis and Treatment

Acotiamide: First Global Approval

Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine

Dabrafenib: First Global Approval